2.37
+0.02(+0.85%)
Currency In NaN
| Previous Close | 2.35 |
| Open | 2.34 |
| Day High | 2.5 |
| Day Low | 2.32 |
| 52-Week High | 17.31 |
| 52-Week Low | 1.47 |
| Volume | 49,912 |
| Average Volume | 199,796 |
| Market Cap | 57.89M |
| PE | -0.39 |
| EPS | -6.15 |
| Moving Average 50 Days | 2.73 |
| Moving Average 200 Days | 4.4 |
| Change | 0.02 |
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Aug 25, 2025 8:05 PM GMT
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune dis
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune dise
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
May 13, 2025 8:05 PM GMT
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab no